While the agreement with Statkraft is a positive step towards AstraZeneca's sustainability goals, it's not directly related to the company's core business operations or financial performance. Therefore, the impact on the stock price in the short term is likely to be neutral. However, it could enhance the company's reputation and appeal to environmentally conscious investors in the long term.